RNS Number : 7388N

Hikma Pharmaceuticals Plc

22 May 2020

London, May 22, 2020 - Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, today announces that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa(R)1 .

In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa(R) patents owned by Amarin. The District Court decision is currently being appealed.

Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa(R) is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."

(1) Vascepa(R) is a registered trademark of Amarin Pharmaceuticals Ireland Limited.

- ENDS -


Hikma Pharmaceuticals PLC

Susan Ringdal                                +44 (0)20 7399 2760/ +44 7776 
 EVP, Strategic Planning and Global Affairs   477050 
Steve Weiss                                  +1 732 720 2830/ +1 732 788 
 David Belian                                 8279 
 US Communications and Public Affairs         +1 732 720 2814/+1 848 254 4875 
                                              u scommunications @hikma.com 

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.



(END) Dow Jones Newswires

May 22, 2020 02:00 ET (06:00 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Da Ott 2020 a Nov 2020 Clicca qui per i Grafici di Hikma Pharmaceuticals
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Da Nov 2019 a Nov 2020 Clicca qui per i Grafici di Hikma Pharmaceuticals